Corneal Graft Rejection Follow-up
- Author: Jason Jacobs, MD; Chief Editor: Hampton Roy Sr, MD more...
Further Outpatient Care
- Patients should receive follow-up care for corneal graft rejection as needed.
Complications
- Depending on the degree of injury sustained by the graft, graft rejection episodes can progress to graft failure due to rejection.
Prognosis
- The sooner an episode of graft rejection is detected clinically and therapy is begun, the better the prognosis for graft survival. The rate of reversal of corneal endothelial graft rejection has been reported from 50-91%, depending on the clinical setting. In general, the prognosis is good if therapy is immediately instituted.
- Depending on the degree of irreversible damage to the graft endothelium, even markedly edematous grafts may clear again. Once endothelial destruction has progressed to the point where the remaining endothelial function is inadequate to maintain deturgescence, the graft fails and becomes irreversibly edematous. Unfortunately, the endothelium has no or at best a very limited capacity for repair through mitosis.
Patient Education
- No symptoms are related universally to graft rejection.
- Astute patients may complain of a decrease in visual acuity, redness, pain, irritation, and photophobia. Patients may also be asymptomatic.
- Any patient with a corneal graft should be instructed to seek ophthalmologic care urgently if these symptoms persist for more than a few hours.
Lee HS, Kim MS. Influential factors on the survival of endothelial cells after penetrating keratoplasty. Eur J Ophthalmol. Nov-Dec 2009;19(6):930-5. [Medline].
Bertelmann E, Pleyer U. Immunomodulatory therapy in ophthalmology - is there a place for topical application?. Ophthalmologica. Nov-Dec 2004;218(6):359-67. [Medline].
Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. Oct 2001;108(10):1838-44. [Medline].
Boisjoly HM, Tourigny R, Bazin R, Laughrea PA, Dube I, Chamberland G, et al. Risk factors of corneal graft failure. Ophthalmology. Nov 1993;100(11):1728-35. [Medline].
Chen YF, Gebhardt BM, Reidy JJ, Kaufman HE. Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol. Feb 15 1990;109(2):132-7. [Medline].
Hegde S, Beauregard C, Mayhew E. CD4(+) T-cell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis. Transplantation. Jan 15 2005;79(1):23-31. [Medline].
Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology. Jan 1994;101(1):128-33. [Medline].
Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol. May 15 1989;107(5):506-10. [Medline].
Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology. Mar 1991;98(3):329-33. [Medline].
Hwang DG, Stern WH, Hwang PH, MacGowan-Smith LA. Collagen shield enhancement of topical dexamethasone penetration. Arch Ophthalmol. Sep 1989;107(9):1375-80. [Medline].
Khodadoust AA, Silverstein AM. Transplantation and rejection of individual layers of the cornea. In: Investigative Ophthalmologic and Visual Sciences. Vol 8. 180-195.
Reidy JJ, Gebhardt BM, Kaufman HE. The collagen shield. A new vehicle for delivery of cyclosporin A to the eye. Cornea. Jul 1990;9(3):196-9. [Medline].
Smolin G, Thoft RA. The cornea. In: Scientific Foundations and Clinical Practice. 3rd ed. Lippincott William & Wilkins; 1994.
Wang M, Lin Y, Chen J, Liu Y, Xie H, Ye C. Studies on the effects of the immunosuppressant FK-506 on the high-risk corneal graft rejection. Yan Ke Xue Bao. Sep 2002;18(3):160-4. [Medline].
Wilson SE, Kaufman HE. Graft failure after penetrating keratoplasty. Surv Ophthalmol. Mar-Apr 1990;34(5):325-56. [Medline].

